Aribex, a worldwide leader in portable and handheld x-ray products most recognized for its NOMAD portable x-ray device, has been acquired by The KaVo Dental Group, an alliance of world-class dental equipment brands. The acquisition is effective immediately.
Aribex, a worldwide leader in portable and handheld x-ray products most recognized for its NOMAD portable x-ray device, has been acquired by The KaVo Dental Group, an alliance of world-class dental equipment brands. The acquisition is effective immediately.
Aribex has global market-leading technology that serves clinical, remote and mobile facilities throughout the world. Handheld and portable x-ray systems are the fastest growing segment in intraoral x-ray systems and Aribex's innovative products are supported by strong patents, intellectual property and a robust new product pipeline.
According to a statement made by Aribex President Ken Kaufman, KaVo Group shares similar values and a passion for future success.
“We are thrilled to be joining forces with the KaVo Group," said Kaufman. "The KaVo Group combines over 500 years of dental experience with leading global brands and will certainly bolster Aribex’s ability to further accelerate the adoption of handheld x-ray technology."
The KaVo Group consists of market-leading brands such as KaVo, Gendex, DEXIS, i-CAT, Instrumentarium, SOREDEX, Pelton & Crane and Marus. With the acquisition of Aribex, the KaVo Group will reinforce its global imaging footprint and commitment to market-leading innovation.
“We enthusiastically welcome the Aribex team and look forward to further acceleration and expansion of the portable x-ray market,” said Henk van Duijnhoven, Senior Vice President, Dental. “The synergies across our platform are immense from integrated R&D, advances in workflow, technology integration and a passion to advance the quality of care that our health care providers deliver. We also share a passion for serving our dealer partners with excellence.”
Integration efforts between Aribex and the KaVo Group are underway. The group does not anticipate any significant changes that would affect relationships with dealers, suppliers or users.
The transaction is subject to regulatory approval and customary closing conditions, including the absence of a material adverse change with respect to the acquired business. Statements in this document that are not strictly historical, including statements regarding the proposed acquisition, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined company and any other statements about managements’ future expectations, beliefs, goals, plans or prospects that may constitute forward-looking statements. These are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward looking statements.
Maximizing Value: The Hidden Benefits of Preventing Hospital-Acquired Pneumonia Through Oral Hygiene
September 10th 2024Originally posted on Infection Control Today. Hospital-acquired pneumonia (HAP) is a significant infection prevention concern, leading to high patient mortality, increased health care costs, and ICU usage. Oral hygiene is an effective preventive measure.
Restoring Severe Tetracycline-Stained Teeth and Correcting Protruding Anterior Teeth
September 10th 2024In this case presentation, IPS e.max and other Ivoclar products are used to remove tetracycline stains, pull back the splaying of the upper anterior teeth, and deliver a great new smile to the patient.